• Suzhou Ribo Life Science proposed amendments to its articles of association to reflect increased registered capital.
• Registered capital would rise from RMB 170.55 million to RMB 184.64 million through issuance of 14,087,085 new H Shares.
• The share issuance would fund acquisition of the remaining 49.71% stake in Ribocure Pharmaceuticals.
• Amended articles would take effect upon approval at an extraordinary general meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261019-12376113), on October 19, 2026, and is solely responsible for the information contained therein.